Santalum album serum - Santalis

Drug Profile

Santalum album serum - Santalis

Alternative Names: Albuterpenoid - Santalis Pharmaceuticals; East Indian Sandalwood Oil (EISO) serum; SAN 021

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santalis Pharmaceuticals
  • Class Anti-infectives; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Plaque psoriasis

Most Recent Events

  • 14 Dec 2017 Santalis Pharmaceuticals completes a phase II trial for Plaque psoriasis in USA (NCT03000608)
  • 17 May 2017 Phase-II clinical trials in Plaque psoriasis in USA (Topical) (NCT03000608)
  • 19 Dec 2016 Santalis Pharmaceuticals plans a phase II trial for Plaque psoriasis in USA (Topical) (NCT03000608)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top